Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CD33

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: CD33. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-002619-89 Sponsor Protocol Number: B1761031 Start Date*: 2019-06-05
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTOR...
    Medical condition: relapsed or refractory CD33-positive acute myeloid leukaemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001918-13 Sponsor Protocol Number: Hovon 43 Start Date*: 2008-01-17
    Sponsor Name:University of Wales College of Medicine
    Full Title: Randomised induction and post induction therapy in older patients (>=61 years of age) with acute myeloid leukaemia (AML) and refractory anaemia with excess blasts (RAEB, RAEB-t)
    Medical condition: Acute Myeloid Leukaemia (AML) Refractory Anaemia with Excesss Blasts (RAEB)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-001321-68 Sponsor Protocol Number: B1761026 Start Date*: 2018-05-22
    Sponsor Name:Pfizer, Inc.
    Full Title: Gemtuzumab Ozogamicin (mylotarg (registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/refractory Acute Myelogenous Leukemia Who May Benefit From Treatm...
    Medical condition: Acute Myelogenous Leukemia, including myelodysplastic syndrome and acute promyelocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-005248-26 Sponsor Protocol Number: AML 07 Start Date*: 2008-05-29
    Sponsor Name:AZIENDA OSPEDALIERA S. MARIA DELLA MISERICORDIA
    Full Title: INDUCTION, CONSOLIDATION AND INTENSIFICATION PROTOCOL FOR PATIENTS YOUNGER THAN 66 YEARS WITH PREVIOUSLY UNTREATED CD33 POSITIVE ACUTE MYELOID LEUKEMIA (AML)
    Medical condition: newly diagnosed (untreated) and CD 33 positive AML, under 66 years.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002933-36 Sponsor Protocol Number: ALFA-0701 Study (Mylofrance 3) Start Date*: 2007-11-02
    Sponsor Name:CH-Versailles
    Full Title: Etude de phase 3 randomisée multicentrique étudiant l’effet de l’addition de l’anticorps monoclonal Gemtuzumab Ozogamicin (Mylotarg) utilisé en doses fractionnées au traitement d’induction et de co...
    Medical condition: The standard regimen for AML is the with Mylotarg, 3 mg/m2 given on days 1,4 and 7.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000640-91 Sponsor Protocol Number: CMA-RC-03 Start Date*: 2005-06-10
    Sponsor Name:Institut de Recerca Hospital Sta. Creu i St. Pau
    Full Title: Treatment for acute myeloid leukemia (AML) during its first complete remision with the monoclonal antibody Mylotarg ® (anti-CD33/calicheamicina) pre- and post- autologous transplant of hematopoieti...
    Medical condition: Acute myeloid leukemia (AML) during its first complete remision and with high relapse risk, pre- and post- autologous hematopoiteic transplant
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000579-10 Sponsor Protocol Number: PEANUT Start Date*: 2019-03-20
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: An open label, single-arm, phase 2 study of pembrolizumab and nanoparticle albumin-bound paclitaxel in patients with metastatic urothelial carcinoma after chemotherapy failure; the PEANUT study
    Medical condition: Advanced or metastatic urothelial carcinoma of the bladder or urinary tract relapsed or refractory to chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002428-36 Sponsor Protocol Number: RG_19-271 Start Date*: 2020-12-02
    Sponsor Name:University of Birmingham
    Full Title: A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) or relapsed/refractory solid tumours
    Medical condition: Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) and relapsed/refractory solid tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021428 - Immune system disorders 10071583 Haemophagocytic lymphohistiocytosis PT
    21.1 10021428 - Immune system disorders 10053867 Macrophage activation syndrome LLT
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-000589-31 Sponsor Protocol Number: NEMESIS Start Date*: 2018-02-02
    Sponsor Name:SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA
    Full Title: multi stage phase II trial of Nivolumab (an anti –PD-1) in patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Medical condition: patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005446-11 Sponsor Protocol Number: FFM-CIK-CellStudy01 Start Date*: 2015-05-28
    Sponsor Name:Goethe-University Frankfurt
    Full Title: A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplasti...
    Medical condition: relapsing acute leukemia, relapsing myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000835 Acute leukemia LLT
    17.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003863-23 Sponsor Protocol Number: TUD-MOSAIC-075 Start Date*: 2020-07-03
    Sponsor Name:Technische Universität Dresden
    Full Title: Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia
    Medical condition: Patients with newly diagnosed acute myeloid leukemia (AML) fit for intensive curative treatment displaying a cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or FL...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005024-10 Sponsor Protocol Number: I6F-MC-JJCB Start Date*: 2015-07-29
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients
    Medical condition: T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005317-68 Sponsor Protocol Number: ACE-CL-208 Start Date*: 2016-05-16
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
    Medical condition: High Risk Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004761-17 Sponsor Protocol Number: SG033-0003 Start Date*: 2008-05-14
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older with Previo...
    Medical condition: acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) HU (Prematurely Ended) AT (Completed) PL (Prematurely Ended) BG (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-002195-90 Sponsor Protocol Number: SPON1334-14 Start Date*: Information not available in EudraCT
    Sponsor Name:Cardiff University
    Full Title: Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome (AML19)
    Medical condition: Acute myeloid leukaemia High Risk Myelodysplastic Syndrome (trial arm for this patient group is now closed awaiting final analysis)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004366-18 Sponsor Protocol Number: MAZEPPA_D19-02 Start Date*: 2020-03-03
    Sponsor Name:GERCOR
    Full Title: MAZEPPA: Phase II PRODIGE-GERCOR study to evaluate MAintenance therapy with olaparib or selumetinib plus durvalumab according to BRCAness and KRAS somatic status Personalized in metastatic Pancreat...
    Medical condition: Metastatic Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002743-89 Sponsor Protocol Number: S0106 Start Date*: 2007-04-10
    Sponsor Name:Southwest Oncology Group (SWOG)
    Full Title: A PHASE III STUDY OF THE ADDITION OF GEMTUZUMAB OZOGAMICIN (MYLOTARG®) DURING INDUCTION THERAPY VERSUS STANDARD INDUCTION WITH DAUNOMYCIN AND CYTOSINE ARABINOSIDE FOLLOWED BY CONSOLIDATION AND SUBS...
    Medical condition: Previously untreated de novo acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003913-32 Sponsor Protocol Number: HeLeNe-18-02 Start Date*: 2020-11-18
    Sponsor Name:Ruprecht-Karls-University of Heidelberg Medical Faculty represented in law by Heidelberg University Hospital
    Full Title: Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without ...
    Medical condition: acute myeloid leukemia (AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002892-30 Sponsor Protocol Number: 1315.2 Start Date*: 2016-04-14
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: An open-label, Phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine in patients with acute myel...
    Medical condition: patients with acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001209-64 Sponsor Protocol Number: BRD 06/10-I Start Date*: 2007-08-16
    Sponsor Name:Centre Hospitalier Universitaire de Nantes
    Full Title: Etude multicentrique de phase III randomisée ouverte testant l’efficacité du gemtuzumab ozogamycin (MYLOTARG®) en association avec la chimiothérapie intensive chez les patients de 18 à 60 ans attei...
    Medical condition: leucémie aiguë myéloblastique (LAM) avec cytogénétique intermédiaire
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000878 Acute myeloblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 12:27:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA